Investigational Site Number :2330001

Tallinn 13419

0 studies enrolling now · 12 studies all time

What they study most

Chronic Kidney Diseases, Giant Cell Arteritis, Heart Failure, Malignant Solid Tumor, Polymyalgia Rheumatica, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis, Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Systemic Sclerosis, Type 2 Diabetes Mellitus

Studies at this site

• A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. — Running, not enrolling
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) — Completed
• Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis — Completed
• Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis — Completed
• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) — Completed
• A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors — Completed
• Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk — Stopped early
• Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica — Stopped early
• Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA — Stopped early
• Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period — Completed
• Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis — Completed
• Effect of Efpeglenatide on Cardiovascular Outcomes — Stopped early